HCM – HUTCHMED (China) Limited
HUTCHMED (China) LimitedHCM
$13.81Name : HUTCHMED (China) Limited
Sector : Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Mark. Cap: $2,494,105,856.00
EPSttm : 2.65
HUTCHMED (China) Limited
$13.81
2.47%$0.35
HCM — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
0.16
Margin Of Safety %
Put/Call OI Ratio
1.17
EPS Next Q Diff
EPS Last/This Y
EPS This/Next Y
0.14
Price
13.77
Target Price
21.23
Analyst Recom
1.33
Performance Q
2.14
Upside
564.0%
Beta
0.44
Ticker: HCM
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-02 | HCM | 13.82 | 1.57 | 0.00 | 172 |
| 2026-03-03 | HCM | 13.46 | 1.57 | 0.00 | 172 |
| 2026-03-04 | HCM | 13.61 | 1.57 | 0.00 | 172 |
| 2026-03-05 | HCM | 13.86 | 1.57 | 0.00 | 172 |
| 2026-03-06 | HCM | 13.73 | N/A | N/A | 0 |
| 2026-03-09 | HCM | 13.84 | N/A | N/A | 0 |
| 2026-03-10 | HCM | 13.8 | 1.57 | 999.99 | 172 |
| 2026-03-11 | HCM | 14.63 | 1.57 | 999.99 | 172 |
| 2026-03-12 | HCM | 14.09 | 1.57 | 999.99 | 172 |
| 2026-03-13 | HCM | 14.19 | 1.57 | 999.99 | 172 |
| 2026-03-17 | HCM | 14.28 | 1.57 | 0.00 | 172 |
| 2026-03-18 | HCM | 14.17 | 1.46 | 0.00 | 177 |
| 2026-03-19 | HCM | 13.96 | 1.36 | 999.99 | 182 |
| 2026-03-20 | HCM | 13.9 | 1.36 | 999.99 | 182 |
| 2026-03-23 | HCM | 14.03 | 1.38 | 999.99 | 183 |
| 2026-03-24 | HCM | 14.09 | 1.38 | 999.99 | 183 |
| 2026-03-25 | HCM | 14.19 | 1.16 | 999.99 | 166 |
| 2026-03-26 | HCM | 14.08 | 1.17 | 999.99 | 167 |
| 2026-03-27 | HCM | 13.87 | 1.17 | 999.99 | 167 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-02 | HCM | 13.79 | - | -63.6 | 1.45 |
| 2026-03-03 | HCM | 13.43 | - | -65.5 | 1.45 |
| 2026-03-04 | HCM | 13.72 | - | -68.3 | 1.45 |
| 2026-03-05 | HCM | 13.85 | - | -68.2 | 1.45 |
| 2026-03-06 | HCM | 13.78 | - | -65.9 | 1.45 |
| 2026-03-09 | HCM | 13.81 | - | -66.3 | 0.37 |
| 2026-03-10 | HCM | 13.80 | - | -545.7 | 0.34 |
| 2026-03-11 | HCM | 14.68 | - | -550.1 | 0.51 |
| 2026-03-12 | HCM | 14.15 | - | -545.1 | 0.51 |
| 2026-03-13 | HCM | 13.89 | - | -547.5 | 0.40 |
| 2026-03-17 | HCM | 14.38 | - | -491.2 | 0.40 |
| 2026-03-18 | HCM | 14.18 | - | -492.0 | 0.40 |
| 2026-03-19 | HCM | 13.91 | - | -492.6 | 0.40 |
| 2026-03-20 | HCM | 13.94 | - | -491.3 | 0.40 |
| 2026-03-23 | HCM | 13.95 | - | -491.8 | 0.40 |
| 2026-03-24 | HCM | 14.03 | - | -491.9 | 0.40 |
| 2026-03-25 | HCM | 13.95 | - | -491.9 | 0.40 |
| 2026-03-26 | HCM | 13.92 | - | -492.2 | 0.40 |
| 2026-03-27 | HCM | 13.77 | - | -492.1 | 0.38 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-02 | HCM | 0.00 | -0.85 | 0.18 |
| 2026-03-03 | HCM | 0.00 | -0.85 | 0.18 |
| 2026-03-04 | HCM | 0.00 | -0.85 | 0.18 |
| 2026-03-05 | HCM | 0.00 | -0.85 | 0.18 |
| 2026-03-06 | HCM | 0.00 | -0.85 | 0.18 |
| 2026-03-09 | HCM | 0.00 | -0.93 | 0.18 |
| 2026-03-10 | HCM | 0.00 | -0.93 | 0.18 |
| 2026-03-11 | HCM | 0.00 | -0.93 | 0.19 |
| 2026-03-12 | HCM | 0.00 | -0.93 | 0.19 |
| 2026-03-13 | HCM | 0.00 | -0.93 | 0.19 |
| 2026-03-17 | HCM | 0.00 | -0.74 | 0.19 |
| 2026-03-18 | HCM | 0.00 | -0.74 | 0.19 |
| 2026-03-19 | HCM | 0.00 | -0.74 | 0.19 |
| 2026-03-20 | HCM | 0.00 | -0.74 | 0.19 |
| 2026-03-23 | HCM | 0.00 | -0.72 | 0.19 |
| 2026-03-24 | HCM | 0.00 | -0.72 | 0.19 |
| 2026-03-25 | HCM | 0.00 | -0.72 | 0.16 |
| 2026-03-26 | HCM | 0.00 | -0.72 | 0.16 |
| 2026-03-27 | HCM | 0.00 | -0.72 | 0.16 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
Avg. EPS Est. Next Quarter
Insider Transactions
Institutional Transactions
-0.72
Beta
0.44
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
99
Growth Score
56
Sentiment Score
66
Actual DrawDown %
68.7
Max Drawdown 5-Year %
-82.2
Target Price
21.23
P/E
5.26
Forward P/E
30.04
PEG
P/S
4.38
P/B
1.95
P/Free Cash Flow
EPS
2.62
Average EPS Est. Cur. Y
0.38
EPS Next Y. (Est.)
0.52
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
83.28
Relative Volume
0.9
Return on Equity vs Sector %
9.6
Return on Equity vs Industry %
29.8
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.01
EBIT Estimation
-492.1
◆
HCM
Healthcare
$13.81
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
42
Range 1M
39.8%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-87.8%
EPS NY
44.9%
52W%
29.2%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+38.1% upside
Upside
+38.1%
Quality
99
HUTCHMED (China) LimitedSector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 1796
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
HCM
Latest News
—
Caricamento notizie per HCM…
stock quote shares HCM – HUTCHMED (China) Limited Stock Price stock today
news today HCM – HUTCHMED (China) Limited stock forecast ,stock prediction 2023 2024 2025
marketwatch HCM – HUTCHMED (China) Limited yahoo finance google finance
stock history HCM – HUTCHMED (China) Limited invest stock market
stock prices HCM premarket after hours
ticker HCM fair value insiders trading